Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1987 · 2.8K citations

Pharmacy, Immunology, Oncology +14

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1985 · 2.6K citations

Medicine, Immunology, Oncology +15

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

Steven A. Rosenberg, Michael T. Lotze, James Chih‐Hsin Yang et al. · Annals of Surgery · 1989 · 1K citations

Medicine, Immunology, Oncology +17

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

D Liénard, Patricia Ewalenko, Jean-Baptiste Delmotte et al. · Journal of Clinical Oncology · 1992 · 723 citations

Pharmacy, Oncology, Pharmacotherapy +17